The Latest Breaking News from Lilly

Eli Lilly & Co., one of Indiana’s largest employers, said the state’s freshly passed restrictions on abortion would force the drugmaker to “plan for more employment growth outside our home state.”

Pharmaceutical giant Eli Lilly is headquartered in Indianapolis and employs more than 10,000 people in the state

Kerry says her “health anxiety” causes her to constantly worry about dying young and she would love for her teenage daughter Lilly to have a child of her own

A few days ago, a university headhunter reached out to Elizabeth T. Jacobs, a professor of epidemiology at the University of Arizona, to gauge her interest in moving to a leading university in Texas.

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …